Voyager Therapeutics (STU:VT6) ROCE %: -57.01% (As of Mar. 2026)

What is Voyager Therapeutics ROCE %?

Voyager Therapeutics STU:VT6 55 ROCE % is -57.01% as of Mar. 2026. GuruFocus rates STU:VT6 with a GF Score™ of 55/100 and a GF Value™ of €1.52 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Voyager Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -57.01%.

Voyager Therapeutics (STU:VT6) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Voyager Therapeutics ROCE % Related Terms

Voyager Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics ROCE % Chart

Voyager Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-40.79

-46.07

64.89

-26.93

-43.26

Voyager Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-41.58	-47.71	-45.50	-50.10	-57.01

55GF Score

Voyager Therapeutics Inc STU:VT6

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Voyager Therapeutics ROCE % Calculation

Voyager Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-112.595	/	( ( (375.363 - 47.548)	+	(215.448 - 22.666) )	/ 2 )
	=	-112.595	/	( (327.815	+	192.782)	/ 2 )
	=	-112.595	/	260.2985
	=	-43.26 %

Voyager Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-104.736	/	( ( (215.448 - 22.666)	+	(189.716 - 15.097) )	/ 2 )
	=	-104.736	/	( ( 192.782	+	174.619 )	/ 2 )
	=	-104.736	/	183.7005
	=	-57.01 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -57.01% mean?

Voyager Therapeutics (STU:VT6) has a ROCE % of -57.01% as of Mar. 2026.

Is Voyager Therapeutics' ROCE % too high?

Voyager Therapeutics' current ROCE % is -57.01%. Overall, Voyager Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Voyager Therapeutics' ROCE % compare to CRBU and OBIO?

Voyager Therapeutics' ROCE % of -57.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Voyager Therapeutics's current ROCE % is -57.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Voyager Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Voyager Therapeutics (STU:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.52, compared to a current price of €3.22 — trading 112.1% above its estimated fair value. The current ROCE % is -57.01%. Voyager Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Voyager Therapeutics (STU:VT6), the current ROCE % is -57.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (STU:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €3.22 is trading 112.1% above its estimated GF Value™ of €1.52. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:VT6:

ROCE %: -57.01%
GF Value™: €1.52 vs. price of €3.22 (112.1% above fair value)
GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the STU:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies CRBU OBIO WHWK NKTX IKT CAMP NERV YDES ALEC SLGL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges VYGR:USA VYGR:Mexico VT6:Germany

Address 75 Hayden Avenue, Lexington, MA, USA, 02421

Website https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

55GF Score

Get the complete analysis for STU:VT6

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.22

Price

€1.52

GF Value

View STU:VT6 Analysis

See ROCE % data for all stocks →